Pfizer's recent stock decline may not dampen long-term prospects. Return on Equity (ROE) is crucial to evaluate growth efficiency. With a 12% ROE, Pfizer's earnings growth lags behind the industry average, possibly due to factors like dividend payouts or competitive pressures.